15 Posts From ASCO24 Day 1 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May 31st to June 4th 2024.
Our team at OncoDaily selected the most important posts from Day 1 of ASCO24 that you should not miss.
Ready, set, go at ASCO24 Day 1. Looking forward to groundbreaking precision medicine treatments, visionary insights, and state-of-the-art research at the 2024 ASCO Annual Meeting.
Most importantly meeting with all amazing oncology colleagues from everywhere.
Only a few times you tear up in a presentation. Dr. Fumiko Ladd Chino shares how pre-authorizations negatively affect our patients – with a focus on pain control.
Delays caused: ER visits, out of pocket expenses and unnecessary suffering.
Dr. Li Zhang at ASCO24 presents phase III HARMONi-A study of chemotherapy plus ivonescimab (PD1/VEGF bispecific) vs placebo in patients with EGFR NSCLC post TKI.
Nothing makes me happier than women supporting women! Great panel and turnout with some amazing co-panelists at ASCO24.
The obligatory Day 1 ASCO24 post.
A sunny day in the windy city!
What I’ve learnt so far at my first ASCO..
1. Bring lunch – the queues are crazy.
2. Take a break Lakeside with a fantastic view of Lake Michigan and play cornhole.
3. Turn up to any talk and hour early – even the overflow rooms were overflowed.
4. Wear comfortable shoes… the venue is massive.
If you’d like to meet up to talk personalised medicine and diagnostics – pop me a message!
Celebrating another milestone with CancerXMoonshot. Together we are changing the future of cancer care for the better, through the largest public-private collaboration!
The Annual Meeting is about to start! The Global Oncology Community of Practice will hold its first in-person meeting today at 1 PM EST in room S103. We hope to see you there!
Starting off ASCO24 with an early flight to Chicago Day 1 Agenda: Leveraging social media for career growth with Fumiko Ladd Chino and the Oncology Brothers.
Metastatic NSCLC, Oral Abstracts Session (ADCs, targeted therapy, and more—stay tuned!)
Super proud of Wesley Yip (City of Hope) who was presented today with an ASCO CDA at ASCO24! So grateful to our SWOG patient advocate extraordinairre who helped us with our grant!
Check out the latest in today’s ASCO24 Daily News! ASCO Communities of Practice Enhance Education and Networking with Mazie Tsang.
Node-negative subanalysis of NATALEE (n=613). Mostly includes patients with T2 disease (75%), virtually all with G2-3 disease.
Consistent benefit in iDFS (93.2% vs 90.6%, HR 0.72), DDFS and DRFS with adjuvant ribociclib. Safety also consistent with ITT.
Thrilled to support celebrate the 2024 ASCO and Conquer Cancer YIA and IDEA awardees in GI onc!
Honored to work with these talented physician-scientists. Creating a supportive environment for them to thrive is what it’s all about.
Alliance A091902 study presented by Dr. Juneko Grilley-Olsen of paclitaxel vs paclitaxel plus nivolumab.
Compelling data for scalp angiosarcomas but no obvious improvement of the combo over paclitaxel alone in overall population. More work necessary.
En route to Chicago for my first ASCO24 conference! Excited to present my research, meet some of my favorite researchers, and connect with aspiring oncologists from around the globe.
Still buzzing from our ASCO24 session on Integrating PROs in routine care. It was wonderful to work with Michael Brundage and Amy Geschwender on bringing this session to life.
Thanks to our highly engaged audience for coming and to Michael Fisch for the opportunity!
